Literature DB >> 35090165

Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.

Paul R Wratil1,2, Marcel Stern1, Alina Priller3, Annika Willmann4, Giovanni Almanzar5, Emanuel Vogel4, Martin Feuerherd4, Cho-Chin Cheng4, Sarah Yazici3, Catharina Christa4, Samuel Jeske4, Gaia Lupoli1, Tim Vogt5, Manuel Albanese1, Ernesto Mejías-Pérez1, Stefan Bauernfried6, Natalia Graf4, Hrvoje Mijocevic4, Martin Vu4, Kathrin Tinnefeld4, Jochen Wettengel2,4, Dieter Hoffmann2,4, Maximilian Muenchhoff1,2, Christopher Daechert1, Helga Mairhofer1, Stefan Krebs7, Volker Fingerle8, Alexander Graf7, Philipp Steininger9, Helmut Blum7, Veit Hornung6, Bernhard Liebl8, Klaus Überla9, Martina Prelog5, Percy Knolle10,11, Oliver T Keppler12,13,14, Ulrike Protzer15,16.   

Abstract

Infection-neutralizing antibody responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 vaccination are an essential component of antiviral immunity. Antibody-mediated protection is challenged by the emergence of SARS-CoV-2 variants of concern (VoCs) with immune escape properties, such as omicron (B.1.1.529), which is rapidly spreading worldwide. Here we report neutralizing antibody dynamics in a longitudinal cohort of coronavirus disease 2019 convalescent and infection-naive individuals vaccinated with mRNA BNT162b2 by quantifying SARS-CoV-2 spike protein antibodies and determining their avidity and neutralization capacity in serum. Using live-virus neutralization assays, we show that a superior infection-neutralizing capacity against all VoCs, including omicron, developed after either two vaccinations in convalescents or a third vaccination or breakthrough infection of twice-vaccinated, naive individuals. These three consecutive spike antigen exposures resulted in an increasing neutralization capacity per anti-spike antibody unit and were paralleled by stepwise increases in antibody avidity. We conclude that an infection-plus-vaccination-induced hybrid immunity or a triple immunization can induce high-quality antibodies with superior neutralization capacity against VoCs, including omicron.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35090165     DOI: 10.1038/s41591-022-01715-4

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  52 in total

1.  Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.

Authors:  Thomas Marjot; Christiane S Eberhardt; Tobias Boettler; Luca S Belli; Marina Berenguer; Maria Buti; Rajiv Jalan; Mario U Mondelli; Richard Moreau; Daniel Shouval; Thomas Berg; Markus Cornberg
Journal:  J Hepatol       Date:  2022-07-20       Impact factor: 30.083

2.  Investigating COVID-19 Vaccine Impact on the Risk of Hospitalisation through the Analysis of National Surveillance Data Collected in Belgium.

Authors:  Diana Erazo; Maria F Vincenti-Gonzalez; Joris A F van Loenhout; Pierre Hubin; Mathil Vandromme; Piet Maes; Maxime Taquet; Johan Van Weyenbergh; Lucy Catteau; Simon Dellicour
Journal:  Viruses       Date:  2022-06-16       Impact factor: 5.818

3.  Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.

Authors:  Hye Kyung Lee; Ludwig Knabl; Mary Walter; Ludwig Knabl; Yuhai Dai; Magdalena Füßl; Yasemin Caf; Claudia Jeller; Philipp Knabl; Martina Obermoser; Christof Baurecht; Norbert Kaiser; August Zabernigg; Gernot M Wurdinger; Priscilla A Furth; Lothar Hennighausen
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

Review 4.  Antibody-mediated neutralization of SARS-CoV-2.

Authors:  Henning Gruell; Kanika Vanshylla; Timm Weber; Christopher O Barnes; Christoph Kreer; Florian Klein
Journal:  Immunity       Date:  2022-05-13       Impact factor: 43.474

Review 5.  Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.

Authors:  Cong Sun; Chu Xie; Guo-Long Bu; Lan-Yi Zhong; Mu-Sheng Zeng
Journal:  Signal Transduct Target Ther       Date:  2022-06-28

6.  Diminished Short- and Long-Term Antibody Response after SARS-CoV-2 Vaccination in Hemodialysis Patients.

Authors:  Louise Füessl; Tobias Lau; Isaac Lean; Sandra Hasmann; Bernhard Riedl; Florian M Arend; Johanna Sorodoc-Otto; Daniela Soreth-Rieke; Marcell Toepfer; Simon Rau; Haxhrije Salihi-Halimi; Michael Paal; Wilke Beuthien; Norbert Thaller; Yana Suttmann; Gero von Gersdorff; Ron Regenauer; Anke von Bergwelt-Baildon; Daniel Teupser; Mathias Bruegel; Michael Fischereder; Ulf Schönermarck
Journal:  Vaccines (Basel)       Date:  2022-04-13

7.  [COVID-19 vaccination strategy for employees of German hospitals: results of a survey of infection control practitioners within the B-FAST project].

Authors:  Simone Scheithauer; Anna Bludau; Stephanie Heinemann; Martina Anton; Percy Knolle
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-10-21       Impact factor: 1.595

8.  COVID-19 vaccines - common misperceptions, false claims and myths explained.

Authors:  Carsten Watzl
Journal:  Eur J Immunol       Date:  2022-04-06       Impact factor: 6.688

9.  Vaccination versus SARS-CoV-2 Omicron: three vaccine doses win the battle.

Authors:  Grzegorz Maria Popowicz; Krzysztof Pyrc; Kamyar Hadian
Journal:  Signal Transduct Target Ther       Date:  2022-04-27

10.  Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants.

Authors:  David Peterhoff; Sebastian Einhauser; Stephanie Beileke; Hans-Helmut Niller; Felix Günther; Michael Schachtner; Benedikt Asbach; Philipp Steininger; Matthias Tenbusch; Antonia S Peter; Andre Gessner; Ralph Burkhardt; Iris M Heid; Ralf Wagner; Klaus Überla
Journal:  Vaccines (Basel)       Date:  2022-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.